Copyright
©The Author(s) 2018.
World J Gastrointest Oncol. Nov 15, 2018; 10(11): 370-380
Published online Nov 15, 2018. doi: 10.4251/wjgo.v10.i11.370
Published online Nov 15, 2018. doi: 10.4251/wjgo.v10.i11.370
Immunohistochemical marker criteria present | Intestinal type | Pancreatobiliary type positive | Mixed/Ambiguous type | Note |
Ang et al[12] (MUC1, MUC2, CDX2, CK20) | Positive CK20 or CDX2 or MUC2, and negative MUC1 Positive CK20 and CDX2, and MUC2 and any MUC1 | Positive MUC1 and negative CDX2, and negative MUC2 and any CK20 | All other combinations | |
Chang et al[13] (MUC1, CDX2) | Positive CDX2 or negative MUC1 | Negative CDX2 and positive MUC1 | Not applicable | CDX2 positivity based on H score (percentage of positive cells × intensity of staining) > 35 MUC1 positivity based on any staining |
Gingras et al[17] (MUC1, CDX2) | Ratio of the CDX2/MUC1 H score ≥ 2 | Ratio of the CDX2/MUC1 H score < 0.5 | Ratio of CDX2/MUC1 H score ≥ 0.5 and < 2 | Use only MUC1 and CDX2 as per Chang et al[13], with H scores for both CDX2 and MUC1 |
Mafficini et al[16] (MUC1, MUC2, CDX2, CK20) | Positive CK20 or CDX2 or MUC2, and negative MUC1 | Positive MUC1 and negative CDX2, and negative MUC2 and any CK20 | All other combinations |
- Citation: Pea A, Riva G, Bernasconi R, Sereni E, Lawlor RT, Scarpa A, Luchini C. Ampulla of Vater carcinoma: Molecular landscape and clinical implications. World J Gastrointest Oncol 2018; 10(11): 370-380
- URL: https://www.wjgnet.com/1948-5204/full/v10/i11/370.htm
- DOI: https://dx.doi.org/10.4251/wjgo.v10.i11.370